Scohia Pharma Inc.
Latest From Scohia Pharma Inc.
Pharma Q2 Results Preview: Pfizer, Teva, Shire, Sanofi And Novo Nordisk
Stakeholders are eager for details on the Takeda/Shire merger and on what Trump said to Pfizer CEO Ian Read to cause the recent about-face on price increases. Other key topics will be status updates on Teva's Copaxone franchise and on Novo Nordisk's oral semaglutide.
Takeda Poised To Move Into Pharma Top 10 With Shire Combination
Takeda is clearly keen on Shire's rare disease therapies, but the future of the ophthalmology business, and notably the dry eye drug Xiidra, is less certain. The shutters may close on Shire's headquarters in Ireland as well.
Deals Shaping The Medical Industry, April 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2017.
Company Information
- Industry
- Pharmaceuticals
- Therapeutic Areas
- Cardiovascular
- Metabolic Disorders
- Renal System
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
Asia
-
Pacific Rim
-
Japan
-
Japan
-
Pacific Rim
-
Asia
- Parent & Subsidiaries
- Scohia Pharma Inc.
- Senior Management
- Yoichi Okumura, CEO
- Contact Info
-
Scohia Pharma Inc.
26-1, Muraoka-Higasji 2-chome
Fujisawa
Kanagawa,
Japan
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice